X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Arcatus is a proprietary suspension of the corticosteroid triamcinolone acetonide for administration to the suprachoroidal space for the treatment of macular edema associated with uveitis and is referred as Xipere, approved in United States.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Arcatus
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearside Biomedical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
ARVN003 (pilocarpine microdose ophthalmic solution/Microline), a proprietary formulation based on microdosing platform Optejet® for the pharmacologic treatment for presbyopia.
Lead Product(s): Pilocarpine Hydrochloride
Therapeutic Area: Ophthalmology Product Name: MicroLine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eyenovia
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2022
Details:
XIPERE, referred to as ARVN001 by Arctic Vision, is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the suprachoroidal space (SCS®) using Clearside’s patented SCS Microinjector®.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Xipere
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Clearside Biomedical
Deal Size: Undisclosed Upfront Cash: $3.0 million
Deal Type: Licensing Agreement September 09, 2021
Details:
ARVN003 is a pharmacologic treatment for presbyopia. The product is developed based on Optejet, a proprietary micro-dosing administration device utilizing MAP technology, and pilocapine, the well-established ophthalmic medicine for temporary improvement of near vision.
Lead Product(s): Pilocarpine Hydrochloride
Therapeutic Area: Ophthalmology Product Name: MicroLine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eyenovia
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2021
Details:
ARVN001 is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the suprachoroidal space (SCS®) through Clearside’s patented SCS Microinjector®.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Xipere
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearside Biomedical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 15, 2021
Details:
ARVN601 Neuroprotection, in the form of non-IOP-related interventions to prevent or delay glaucomatous neurodegeneration, has been underscored to be an unmet need in the management of glaucoma ever since the 2010 World Glaucoma Association Consensus Meeting.
Lead Product(s): ARVN601
Therapeutic Area: Ophthalmology Product Name: ARVN601
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: University of Hong Kong
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 05, 2021
Details:
Arctic Vision will develop and market ActualEyes’ AE-101, for the treatment of corneal endothelial dysfunction in Greater China and South Korea. ARVN901 (AE-101) is a novel cell-injection therapy developed using cultured hCECs combined with a ROCK inhibitor.
Lead Product(s): Rho-associated kinase-Human corneal endothelial cells
Therapeutic Area: Ophthalmology Product Name: AE101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: ActualEyes
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 14, 2021
Details:
Arctic Vision currently has three late-stage in-licensed products: ARVN001 for uveitic macular edema (UME), ARVN002 for pediatric progressive myopia and ARVN003 for presbyopia.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: ARVN001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Loyal Valley Capital
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 10, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
